• Yan Lin, Lian-Jie Lin, Yu Jin, Yong Cao, Ying Zhang, Chang-Qing Zheng, Jia-Li Liu, and Sheng-Li Yang.
• Department of Gastroenterology, Shengjing Hospital, China Medical University, Sanhao Street No. 36, Heping District, Shenyang 110001, China.
• Biomed Res Int. 2015 Jan 1; 2015: 430185.

BackgroundAberrant expression of high mobility group box-1 protein (HMGB1) contributes to the progression of various inflammatory diseases. This meta-analysis focused on the clinical significance of serum HMGB1 levels in pancreatitis patients, with the goal of building a novel diagnostic score model.MethodWe conducted a meta-analysis by searching in the PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, China BioMedicine (CBM), and China National Knowledge Infrastructure (CNKI) databases without any language restrictions. Studies were pooled and standard mean difference (SMD) and its corresponding 95% confidence intervals (95% CIs) were calculated. Version 12.0 STATA software was used for statistical analysis.ResultsWe performed a final analysis of 841 subjects from 12 clinical case-control studies. The meta-analysis results showed a positive association between serum HMGB1 levels and the progression of pancreatitis. In the subgroup analysis by country, high serum level of HMGB1 may be related to pancreatitis progression in China, Korea, Hungary, and Japan populations (all P < 0.05).ConclusionThe present meta-analysis indicated that serum HMGB1 level was statistically elevated in patients with pancreatitis, and thus serum levels of HMGB1 could be determined to be a useful biomarker for pancreatitis patients.

11 keywords...

hide…